Freestone Grove Partners LP Protagonist Therapeutics, Inc Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Freestone Grove Partners LP holds 6,644 shares of PTGX stock, worth $255,727. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,644Holding current value
$255,727% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$228 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$222 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$212 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$162 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$128 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.89B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...